ClinicaliQ Trial Snapshot
- The PROSECCA Study, Answering New Questions in Prostate Cancer — Recruiting • Oncology • NCT06714630.
- What is being tested: The PROSECCA study evaluates radiotherapy techniques and strategies for prostate cancer treatment, specifically investigating methods to minimise damage to healthy tissues while effectively targeting cancer lesions.
- Patient eligibility overview: The study targets prostate cancer patients requiring radiotherapy as part of their treatment pathway, focusing on those where the balance between cancer control and toxicity to surrounding normal tissues is clinically relevant.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Nearly half of all cancer patients receive radiotherapy as part of their treatment and although it is effective at destroying cancerous lesions deep within the body, this comes at the cost of damaging healthy, or normal, tissues. With 50% of cancer patients surviving for 10 years or more, these patients can be left with life-changing side effects from their radiotherapy. It is clear that more must be done to limit damage to normal healthy tissue without compromising annihilation of the tumour and curing patients. The key to this is personalising…
Eligibility Snapshot
- : * External beam radiotherapy delivered by a linear accelerator * Prostate Specific Antigen (PSA) recorded at regular intervals after radiotherapy * Minimum of 10 year survival post-radiotherapy * Diagnostic Computerised Tomography (CT) acquired * Radiotherapy planning CT acquired * Radiotherapy treatment planning data available * Corresponding healthcare data available to infer toxicity events (ref previous work by Lemanska et al)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.